DowJones News
15 Sep, 2021 06:33

DJ Coegin Pharma AB: BioStock: Coegin Pharma on the cusp of initiating COAK Study

Nordic biotech Coegin Pharma reached a key milestone this summer by 
receiving the green light from the Danish Medicines Agency to begin the 
Copenhagen Actinic Keratosis Study with lead candidate AVX001. Now, the 
company has also received a conditional approval from the Ethics 
Committee, meaning that the clinical trial will be initiated after 
making slight adjustments to patient information material. BioStock 
spoke with Coegin's CEO Tore Duvold to discuss what this all means. 
 
Read the interview with Tore Duvold at biostock.se: 
 
https://www.biostock.se/en/2021/09/coegin-pharma-on-the-cusp-of 
-initiating-coak-study/ 
 
This is a press release from BioStock - Connecting Innovation & 
Capital. https://www.biostock.se/ 
 
 
 
------------------------------------------------------------ 
This information was brought to you by Cision http://news.cision.com 
https://news.cision.com/coegin-pharma-ab/r/biostock--coegin-pharma-on-the-cusp-of-initiating-coak-study,c3415061 
 

(END) Dow Jones Newswires

September 15, 2021 02:33 ET (06:33 GMT)


News Source: © 2021 Web Financial Group (UK) Limited. All rights reserved and terms of use apply.

Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.

 

Important Legal Notice about News Sources

Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author or publisher.

We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.